Gastrointestinal Stromal Tumors (GISTs): Comprehensive Diagnosis and Surgical Approaches

Gastrointestinal Stromal Tumors (GISTs): Diagnosis and Surgical Treatment
Gastrointestinal Stromal Tumors (GISTs) are rare, yet highly significant, tumors that arise in the digestive tract. Although relatively uncommon, their impact is critical due to their potential for malignancy and the complex nature of their treatment. GISTs predominantly originate from the stomach, but they can also be found along the entire gastrointestinal (GI) tract, including the small intestines, esophagus, and rectum. Understanding their presentation, diagnosis, and treatment options is crucial for both practicing physicians and medical students aiming to deepen their knowledge of oncologic surgery.

What Are Gastrointestinal Stromal Tumors?
GISTs are a type of sarcoma, meaning they arise from the connective tissue rather than epithelial cells, which are the usual origins of more common cancers like adenocarcinoma. Most GISTs arise from specialized nerve cells located within the walls of the digestive tract known as the interstitial cells of Cajal (ICCs), which regulate gut motility. The development of GISTs is primarily linked to mutations in the KIT gene or PDGFRA gene, which results in unregulated cell growth. This mutation leads to the uncontrolled activation of a tyrosine kinase receptor, driving tumor proliferation.

Epidemiology of GISTs
While GISTs represent only about 1% of all GI cancers, their discovery has surged with advances in diagnostic imaging and molecular pathology. Approximately 6,000 new cases are diagnosed annually in the United States, making GISTs one of the most common mesenchymal tumors of the gastrointestinal tract. The incidence of GISTs tends to increase with age, with most patients diagnosed between 50 and 70 years. There is no significant gender predisposition, though some data suggest a slight male predominance.

Clinical Presentation
The symptoms of GISTs vary based on the tumor’s size and location. Early-stage GISTs are often asymptomatic and may be discovered incidentally during imaging or endoscopy for unrelated issues. Larger tumors, however, may cause a variety of symptoms depending on their location:

• Stomach and Small Intestine: Abdominal pain, bloating, early satiety, and sometimes gastrointestinal bleeding (manifesting as melena or hematemesis).
• Esophagus: Dysphagia or difficulty swallowing.
• Rectum: Rectal bleeding or changes in bowel habits.

Given their ability to grow large without causing obstruction, GISTs can sometimes evade early detection, making their diagnosis more challenging.

Diagnostic Workup
The diagnosis of GISTs often begins with imaging studies. The following are crucial in identifying and characterizing these tumors:

1. Computed Tomography (CT) Scan: A contrast-enhanced CT scan is the most commonly used imaging modality for GISTs. It helps determine the size, location, and extent of the tumor and identifies possible metastases, particularly to the liver or peritoneum. CT is often used for both initial diagnosis and post-treatment monitoring. PET-CT is another valuable tool, particularly in evaluating metabolic activity and assessing treatment response in advanced or recurrent cases.

• Source: https://www.cancer.gov/types/soft-tissue-sarcoma/patient/gist-treatment-pdq

​

2. Endoscopic Ultrasound (EUS): EUS provides a more detailed assessment of the tumor’s origin within the layers of the GI tract, which is critical in differentiating GISTs from other submucosal lesions. EUS can also assist with tissue biopsy via fine-needle aspiration, providing samples for histopathological and molecular analysis.

• Source: https://www.mskcc.org/cancer-care/types/gastrointestinal-stromal-tumor/gist-diagnosis

​

3. Biopsy and Immunohistochemistry: A definitive diagnosis of GIST is confirmed through biopsy, typically during endoscopy or surgery. Immunohistochemical staining is vital, with most GISTs staining positive for CD117 (KIT), a marker for the KIT tyrosine kinase receptor. Around 95% of GISTs express CD117, which helps differentiate them from other soft tissue tumors. DOG1 and PDGFRA are additional markers that can help in cases where CD117 is absent.

• Source: https://www.uptodate.com/contents/g...clinical-presentation-diagnosis-and-pathology

​

Risk Stratification and Prognosis
One of the most important aspects of managing GISTs is determining their risk of recurrence or metastasis after initial treatment. This risk stratification is based on tumor size, mitotic rate (number of dividing cells seen under the microscope), and location. Large tumors (>5 cm), those with high mitotic rates (>5 mitoses per 50 high-power fields), and tumors arising from the small intestine tend to have a higher risk of recurrence.

Surgical Treatment of GISTs
Surgery is the cornerstone of treatment for localized GISTs, offering the only potential for cure. The goal of surgical resection is to completely remove the tumor with negative margins while preserving organ function.

1. Surgical Techniques: Depending on the size and location of the tumor, different surgical approaches can be employed:

• Open Surgery: Traditional open surgery is often necessary for larger GISTs or those located in difficult-to-reach areas. The surgeon makes a large incision in the abdomen to access and remove the tumor.
• Laparoscopic Surgery: Minimally invasive surgery is suitable for smaller tumors, particularly those located in the stomach. Laparoscopy involves smaller incisions and typically leads to quicker recovery times and reduced postoperative pain.
• Organ-Sparing Techniques: Efforts are made to preserve as much of the affected organ as possible. For example, in gastric GISTs, a wedge resection may be performed to remove the tumor while maintaining the stomach's function.

​

2. Surgical Challenges: One of the biggest challenges in GIST surgery is avoiding tumor rupture, which can lead to seeding of the abdominal cavity and increase the risk of recurrence. Therefore, a meticulous surgical technique is crucial.

The Role of Targeted Therapy: Imatinib
While surgery is the first-line treatment for localized GISTs, many patients with advanced, metastatic, or unresectable tumors benefit from targeted therapy. The advent of imatinib (Gleevec), a tyrosine kinase inhibitor (TKI), has revolutionized the treatment of GISTs. Imatinib works by blocking the KIT and PDGFRA receptors, which are mutated in most GIST cases.

• Adjuvant Therapy: For patients at high risk of recurrence after surgery, adjuvant therapy with imatinib is often recommended for at least three years. Studies have shown that this significantly reduces the risk of recurrence and improves overall survival.
• Neoadjuvant Therapy: In some cases, imatinib is given before surgery (neoadjuvant therapy) to shrink the tumor, making it easier to remove. This is particularly useful for large GISTs or those located in anatomically challenging areas.
• Treatment for Metastatic GISTs: For metastatic or unresectable GISTs, imatinib remains the standard of care. The typical starting dose is 400 mg per day, but higher doses may be required for certain mutations, such as PDGFRA exon 18 mutations.
  • Source: https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/treating/targeted-therapy.html

Resistance to Imatinib and Alternative Treatments
While imatinib is highly effective, some patients eventually develop resistance to the drug, often due to secondary mutations in the KIT or PDGFRA genes. In such cases, alternative therapies are considered:

1. Sunitinib (Sutent): This second-line TKI is used for patients who develop resistance to imatinib or cannot tolerate it. Sunitinib targets multiple tyrosine kinases, offering an additional therapeutic mechanism.
2. Regorafenib (Stivarga): Approved as a third-line therapy, regorafenib is used when both imatinib and sunitinib are ineffective.
3. Ripretinib (Qinlock): The newest addition to GIST treatment, ripretinib is a fourth-line treatment approved for patients who have progressed on prior therapies. It inhibits a broad range of KIT and PDGFRA mutations, offering hope for patients with resistant GISTs.

Monitoring and Follow-Up
After surgical resection, regular follow-up is essential to monitor for recurrence. Patients typically undergo surveillance with CT scans or MRI every 3-6 months for the first few years, depending on their risk of recurrence.

Challenges and Future Directions in GIST Treatment
Despite significant advances in the treatment of GISTs, several challenges remain:

1. Drug Resistance: As mentioned earlier, the development of resistance to imatinib and other TKIs is a major hurdle. Ongoing research aims to better understand the mechanisms of resistance and develop new drugs to target resistant tumors.
2. Personalized Medicine: The future of GIST treatment lies in personalized medicine, where therapies are tailored to the specific genetic mutations of each tumor. This approach will likely improve treatment outcomes and reduce the risk of recurrence.
3. Immunotherapy: Although not yet a standard treatment for GISTs, there is growing interest in the use of immunotherapy, such as immune checkpoint inhibitors, to enhance the body’s ability to fight the tumor.

Conclusion
Gastrointestinal Stromal Tumors represent a fascinating area of study in both surgical oncology and molecular medicine. With advancements in diagnostic techniques, surgical options, and targeted therapies like imatinib, the prognosis for patients with GISTs has dramatically improved. However, the complexity of these tumors demands a multidisciplinary approach to treatment, with ongoing research needed to overcome the challenges of drug resistance and recurrence.

Medical students and doctors should stay updated on the latest developments in GIST management, as this field continues to evolve rapidly. Understanding the unique biology of GISTs and their treatment options is essential for providing the best care to patients.